BLCA-4 and UBC combined detection for early diagnosis of bladder cancer

L Cui, M M Sun, Z H Zhao, J P Yang, Y P Zheng, L L He, K S Chen, Q X Fan

Article ID: 4162
Vol 30, Issue 2, 2016
DOI: https://doi.org/10.54517/jbrha4162
Received: 6 June 2022; Accepted: 6 June 2022; Available online: 6 June 2022; Issue release: 6 June 2022

Abstract

The objective of the present study was to report the clinical significance of bladder cancer specific nuclear matrix protein 4 (BLCA-4) and urinary bladder cancer (UBC) on early diagnosis of bladder cancers. Enzyme-linked immunosorbent assay (ELISA) was used to detect BLCA-4 and UBC of 56 bladder cancer patients and 26 patients with urinary tract benign diseases, serving as controls. Urine exfoliated cell test was performed, and then the significance of BLCA-4 and UBC on the diagnosis of bladder cancers was analyzed. The sensitivity of BLCA-4 and UBC of the bladder cancer patients was significantly higher than that of the urine exfoliated cell test (P less than 0.05). The difference of BLCA-4 and UBC was not significant (P >0.05). The difference of BLCA-4 and UBC in the tumors with different gradings and stagings was not significant (P >0.05). Combined detection of BLCA-4 and UBC could improve the diagnosis sensitivity and specificity of bladder cancers with the advantages of high maneuverability, repeatability and objective results.


Keywords

bladder tumor;BLCA-4;UBC;combined detection


References

Supporting Agencies



Copyright (c) 2016 L Cui, M M Sun, Z H Zhao, J P Yang, Y P Zheng, L L He, K S Chen, Q X Fan




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).